Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210328 | 0.84 | SMN1; SMN2 (0.51) | EPHX2SMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL24711308 | 0.75 | HTR2A (0.53) | EPHX2SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL18711646 | 0.73 | ALDH1A1 (0.76) | ALDH1A1MAPTTSHRPKMPKLR | |
| SCHEMBL3920751 | 0.73 | EPHX2 (0.57) | EPHX2ALDH1A1TP53 | |
| SCHEMBL25941353 | 0.72 | ALDH1A1 (0.65) | ALDH1A1MAPTTSHRPKMPKLR | |
| SCHEMBL3920757 | 0.72 | EPHX2 (0.68) | EPHX2SMN1; SMN2TP53 | |
| SCHEMBL22032751 | 0.72 | CYP2D6 (0.61) | SMN1; SMN2ALDH1A1MAPTCYP2D6TSHR | |
| SCHEMBL4554020 | 0.72 | KDM4E (0.61) | SMN1; SMN2ALDH1A1MAPTTSHRCYP2C19 | |
| SCHEMBL20595150 | 0.72 | KDM4E (0.61) | SMN1; SMN2ALDH1A1MAPTTSHRCYP2C19 | |
| SCHEMBL18702061 | 0.71 | ALDH1A1 (0.57) | ALDH1A1MAPTTSHRHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | EPHX2 796/4885SMN1; SMN2 3573/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.